High-throughput Discovery of Antibodies against Understudied Membrane Proteins

针对正在研究的膜蛋白的抗体的高通量发现

基本信息

批准号：
10698472
负责人：
ROSS S CHAMBERS
金额：
$ 29.59万
依托单位：
INTEGRAL MOLECULAR
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10698472
关键词：
Abbreviations Affinity Animals Antibodies Antigens Bacteriophages Binding Biology Biomedical Research Catalogs Cell surface Complex DNA Development Diagnostic Ensure FDA approved Family Flow Cytometry Future G-Protein-Coupled Receptors Genes Genome Health Human Human Genome Immunization Immunize Immunofluorescence Immunologic Industry Ion Channel Membrane Membrane Proteins Messenger RNA Methods Molecular Molecular Conformation Monoclonal Antibodies Pharmaceutical Preparations Pharmacologic Substance Phase Process Proteins Proteome Public Health RNA vaccination Reagent Recombinants Reproducibility Research Serum Specificity System Testing Therapeutic Time United States National Institutes of Health Western Blotting commercialization druggable target experience experimental study high standard human disease immunocytochemistry novel strategies phase 2 study polyclonal antibody programs response timeline tool

项目摘要

ABSTRACT Of the 20,000 genes in the human genome, approximately 4,000 are considered “druggable” by pharmaceuticals. However, less than 10% of these druggable proteins are actually targeted by FDA-approved drugs. In 2014, the Illuminating the Druggable Genome (IDG) project was launched by the NIH in recognition that there is a potentially large number of druggable targets with high therapeutic value that are undiscovered or understudied. The IDG selected 230 G protein-coupled receptors (GPCRs) and ion channels as a focus of their program, as these families make up the largest families of the druggable genome and have high potential to impact human health. Due to their difficult biology, many of them are completely unexplored. To enable this research, the IDG has called for the development of reagents such as monoclonal antibodies (MAbs) against these 230 GPCRs and ion channels, only 10% of which currently have commercially available MAbs. A novel approach to identify membrane protein MAbs in a high-throughput manner is needed to derive MAbs against the entire druggable human membrane proteome.

抽象的在人类基因组的 20,000 个基因中，大约 4,000 个被认为是“可成药的” 然而，只有不到 10% 的可药物蛋白实际上是 FDA 批准的目标。在 201 种药物4中，NIH 启动了阐明可药物基因组 (IDG) 项目以表彰存在大量尚未发现的具有高治疗价值的潜在药物靶点 IDG 选择 230 G 蛋白偶联受体 (GPCR) 和离子通道作为重点研究对象。他们的计划，因为这些家族构成了可成药基因组中最大的家族，并且具有很高的潜力由于其复杂的生物学特性，其中许多尚未被完全探索。 IDG 呼吁开发单克隆抗体 (MAb) 等试剂这 230 个 GPCR 和离子通道，目前只有 10% 有商业化的 MAb 新型。需要以高通量方式鉴定膜蛋白单克隆抗体的方法来衍生针对整个可药物化的人膜蛋白质组。